Geographic tongue clinical response in moderate-to-severe psoriatic patients undergoing secukinumab: a real-life, multicenter retrospective observational study

G Damiani, A Pacifico, P Malagoli, M Bindi, C Maiorana, P Poli, S Taschieri, L Francetti, S Corbella, M Del Fabbro, S Marino, F Spadari, NL Bragazzi, PDM Pigatto

Article ID: 5478
Vol 35, Issue 2S1, 2021
DOI: https://doi.org/10.23812/21-2supp1-32
Received: 9 May 2021; Accepted: 9 May 2021; Available online: 9 May 2021; Issue release: 9 May 2021

Abstract

Geographic tongue (GT), a form of inverse psoriasis, is frequently linked to plaque psoriasis. The objective of the study is to evaluate IL-17 blocker (secukinumab) effect on GT severity. This reallife, multicenter, retrospective observational pilot study evaluated patients with plaque psoriasis and concomitant GT that started in label treatment with secukinumab. Patients were evaluated twice (T0=baseline and T1=after 16 weeks) by a dentist and a dermatologist collecting data on cutaneous Psoriasis Area Severity Index (PASI) and oral statuses using Humes classification of the Geographic Tongue Severity Index (GTASI). Twenty-nine psoriatic patients with GT treated with secukinumab were enrolled for the study. Seventeen patients display type I GT, 6 type II and 6 type III with an overall GTASI of 25.52±9.57 at the baseline (T0). No correlation was found between delta GTASI and delta PASI (r=-0.27, p=0.1551). GTASI decrement from T0 to T1 was statistically significant ([95%CI -26.64 to -19.56], t=-13.36, p<0.0001). Secukinumab may enter in GT therapeutic armamentarium as the first biologic IL-17 blocker in patients with concomitant moderate-to-severe plaque psoriasis.


Keywords

IL-17 blockers;geographic tongue;inverse psoriasis;psoriasis;secukinumab


References

Supporting Agencies



Copyright (c) 2021 G Damiani, A Pacifico, P Malagoli, M Bindi, C Maiorana, P Poli, S Taschieri, L Francetti, S Corbella, M Del Fabbro, S Marino, F Spadari, NL Bragazzi, PDM Pigatto




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).